Eli Lilly & Novo Nordisk – Episode 2018Q3 – The ongoing battle for GLP1 market share

Diabetes rivals Eli Lilly and Novo Nordisk and their smaller diabetes competitors such as Sanofi, Merck, AstraZeneca and Johnson & Johnson have all released their Q3 results. Below is a summary of Novo and Lilly and their shared therapeutic area diabetes and their shared drug class GLP1. GLP1 receptor agonists come with the HbA1c advantages …

Pandora lowers full year guidance

The jewelry maker Pandora, which is still without a CEO, sent out a press release on their Q3 results today. Expected revenue growth for 2018 was revised from 4-7% to 2-4%. Bloomberg: Pandora Plans `Reset’ in Bid to Shore Up Investor Confidence Reuters: Charm-bracelet maker Pandora warns again on sales euronews: Jeweller Pandora cuts 2018 …